BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 11875723)

  • 1. Phase II study of bi-weekly administration of paclitaxel and cisplatin in patients with advanced oesophageal cancer.
    Polee MB; Eskens FA; van der Burg ME; Splinter TA; Siersema PD; Tilanus HW; Verweij J; Stoter G; van der Gaast A
    Br J Cancer; 2002 Mar; 86(5):669-73. PubMed ID: 11875723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of a weekly schedule of a fixed dose of cisplatin and escalating doses of paclitaxel in patients with advanced oesophageal cancer.
    Polee MB; Verweij J; Siersema PD; Tilanus HW; Splinter TA; Stoter G; Van der Gaast A
    Eur J Cancer; 2002 Jul; 38(11):1495-500. PubMed ID: 12110496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of neo-adjuvant chemotherapy with paclitaxel and cisplatin given every 2 weeks for patients with a resectable squamous cell carcinoma of the esophagus.
    Polee MB; Tilanus HW; Eskens FA; Hoekstra R; Van der Burg ME; Siersema PD; Stoter G; Van der Gaast A
    Ann Oncol; 2003 Aug; 14(8):1253-7. PubMed ID: 12881388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus.
    Ilson DH; Ajani J; Bhalla K; Forastiere A; Huang Y; Patel P; Martin L; Donegan J; Pazdur R; Reed C; Kelsen DP
    J Clin Oncol; 1998 May; 16(5):1826-34. PubMed ID: 9586897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of epirubicin, cisplatin and raltitrexed combination chemotherapy (ECT) in patients with advanced oesophageal and gastric adenocarcinoma.
    Mackay HJ; McInnes A; Paul J; Raby N; Lofts FJ; McDonald AC; Soukop M; Fullarton GM; Harris AL; Garcia-Vargas J; Evans TR
    Ann Oncol; 2001 Oct; 12(10):1407-10. PubMed ID: 11762812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer.
    Honecker F; Kollmannsberger C; Quietzsch D; Haag C; Schroeder M; Spott C; Hartmann JT; Baronius W; Hempel V; Kanz L; Bokemeyer C
    Anticancer Drugs; 2002 Jun; 13(5):497-503. PubMed ID: 12045461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of cisplatin preceding gemcitabine in patients with advanced oesophageal cancer.
    Kroep JR; Pinedo HM; Giaccone G; Van Bochove A; Peters GJ; Van Groeningen CJ
    Ann Oncol; 2004 Feb; 15(2):230-5. PubMed ID: 14760114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multi-center phase II trial of weekly paclitaxel plus cisplatin combination chemotherapy in patients with advanced gastric and gastro-esophageal cancer.
    Sun Q; Liu C; Zhong H; Zhong B; Xu H; Shen W; Wang D
    Jpn J Clin Oncol; 2009 Apr; 39(4):237-43. PubMed ID: 19264768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: a randomized phase II study.
    Lee SJ; Kim S; Kim M; Lee J; Park YH; Im YH; Park SH
    BMC Cancer; 2015 Oct; 15():693. PubMed ID: 26468007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I/II study of paclitaxel plus cisplatin as first-line chemotherapy for advanced non-small cell lung cancer: preliminary results.
    Belli L; LeChevalier T; Gottfried M; Adams D; Ruffie P; LeCesne A; Tete L; Pellae-Cosset B
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):29-33. PubMed ID: 8643967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Phase II study of paclitaxel and cisplatin for advanced squamous-cell carcinoma of esophagus].
    Huang J; Cai RG; Meng PJ; Zhang MJ; Cui CX; Yang L; Chu DT; Sun Y; Wang JW
    Zhonghua Zhong Liu Za Zhi; 2004 Dec; 26(12):753-5. PubMed ID: 15733398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I/II study of oxaliplatin and paclitaxel in patients with non-resectable cancer of the oesophagus and adenocarcinoma of the gastro-oesophageal junction: a study of the Arbeitsgemeinschaft Internistische Onkologie.
    Kaechele V; Moehler M; Lutz MP; von Wichert G; Eisele M; Klaus J; Galle PR; Adler G; Seufferlein T
    Cancer Chemother Pharmacol; 2010 May; 66(1):191-5. PubMed ID: 20354701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential therapy in advanced non-small-cell lung cancer with weekly paclitaxel followed by cisplatin-gemcitabine-vinorelbine. A phase II study.
    Feliu J; Martin G; Lizón J; Chacón JI; Dorta J; de Castro J; Rodríguez A; Sánchez Heras B; Torrego JC; Espinosa E; González Barón M;
    Ann Oncol; 2001 Oct; 12(10):1369-74. PubMed ID: 11762806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma.
    Evans TR; Pentheroudakis G; Paul J; McInnes A; Blackie R; Raby N; Morrison R; Fullarton GM; Soukop M; McDonald AC
    Ann Oncol; 2002 Sep; 13(9):1469-78. PubMed ID: 12196374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of a biweekly schedule of a fixed dose of cisplatin with increasing doses of paclitaxel in patients with advanced oesophageal cancer.
    van der Gaast A; Kok TC; Kerkhofs L; Siersema PD; Tilanus HW; Splinter TA
    Br J Cancer; 1999 Jun; 80(7):1052-7. PubMed ID: 10362115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer.
    Ilson DH; Saltz L; Enzinger P; Huang Y; Kornblith A; Gollub M; O'Reilly E; Schwartz G; DeGroff J; Gonzalez G; Kelsen DP
    J Clin Oncol; 1999 Oct; 17(10):3270-5. PubMed ID: 10506629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of docetaxel and cisplatin in patients with recurrent or disseminated squamous-cell carcinoma of the head and neck.
    Specht L; Larsen SK; Hansen HS
    Ann Oncol; 2000 Jul; 11(7):845-9. PubMed ID: 10997812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction.
    Ajani JA; Komaki R; Putnam JB; Walsh G; Nesbitt J; Pisters PW; Lynch PM; Vaporciyan A; Smythe R; Lahoti S; Raijman I; Swisher S; Martin FD; Roth JA
    Cancer; 2001 Jul; 92(2):279-86. PubMed ID: 11466680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer.
    Lordick F; von Schilling C; Bernhard H; Hennig M; Bredenkamp R; Peschel C
    Br J Cancer; 2003 Aug; 89(4):630-3. PubMed ID: 12915869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.